Trial Profile

Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Dexamethasone
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms ALLG MM16

Most Recent Events

13 Jul 2021 Status changed from recruiting to active, no longer recruiting.
04 Dec 2018 Interim results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
19 May 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com